FDA

Jun 07, 2019

In layman’s language, Cluster headache is a headache disorder that occurs in cyclical patterns. The term cluster headache itself defines the condition that these attacks occur in groups, or “clusters.” During a cluster cycle, brief, excruciatingly severe headache attacks recur between 1-8 times per day. Known as on...

May 28, 2019

Stem cells can regenerate heart Researchers at the Icahn School of Medicine, U.S.A in their recent study revealed that stem cells extracted from placenta also known as Cdx2 cells might be able to regenerate heart cells after the heart attack. From the beginning, it has been thought that Cdx2 cells could only ge...

May 21, 2019

FDA approves Fragmin- an anticoagulant for children   The FDA today approved Fragmin for the treatment of blood clots. Pfizer’s candidate Fragmin which was earlier approved for the treatment of only adults suffering from a fatal disease called VTE, which can include deep vein thrombosis (blood clot in the d...

Apr 09, 2019

Anylam, Regeneron to broaden the scope of R&D in Pharma Alnylam in collaboration with Regeneron is expanding its research on NASH. Regeneron with the capability of generating various targets via antibody approach is going to get infused with USD 800 million upfront. The joint deal will help in expanding R&am...

Apr 02, 2019

Selumetinib gets the U.S. Breakthrough Therapy Designation Selumetinib- an investigational drug, for the treatment of pediatric patients aged three years and above suffering from symptomatic and/or progressive, inoperable neurofibromatosis type 1 (NF1), plexiform neurofibromas (PN)- a rare genetic condition, has...

Mar 28, 2019

Saama Technologies raises USD 40 Million to bolster AI Saama Technologies has got a hefty investment of USD 40million to accelerate its Artificial Intelligence and bolster its use in the branch of Life Sciences. This will help the California based data analytics company to innovate, curate and accelerate the cli...

Mar 21, 2019

Biohaven buys PRV from GW Pharmaceuticals for USD 105 million GW Pharmaceuticals has announced its decision to sell its rare pediatric disease priority review voucher (PRV) to Biohaven Pharmaceuticals. The voucher was issued under U.S. Food and Drug Administration programme to accelerate speedy recovery of rare ...

Mar 19, 2019

A New Approach to treat Cystic Fibrosis Researchers at the University of Illinois in Champaign have found that anti-fungal drug amphotericin that helps lung cells to fight chronic bacterial lung infection can help in treating Cystic Fibrosis- a genetic disorder that causes serious damages to lungs. The finding ...

Mar 12, 2019

Stemline gives in-licenses global rights to SL-1001 Stemline Therapeutics, Inc. is a biopharmaceutical company focused on development and commercialization of novel oncology therapeutics, has licensed worldwide rights to a preclinical molecule RET (rearranged during transfection) kinase inhibitor. The RET kinase...

Mar 11, 2019

Technology has made an impact on every field. And Healthcare is no exception. Advances in medical technology have proven to be a game-changer in the health sector. But is the case same when Women healthcare comes to mind? It will not be less than a shock to learn that Women were not included in medical research and...